Swaney W P, Sorgi F L, Bahnson A B, Barranger J A
Department of Human Genetics, Graduate School of Public Health, University of Pittsburgh, PA 15261, USA.
Gene Ther. 1997 Dec;4(12):1379-86. doi: 10.1038/sj.gt.3300529.
Pretreatment of retroviral supernatants with the cationic liposomes DOTMA-DOPE (Lipofectin), DC-Chol-DOPE and DOSPA-DOPE (Lipofectamine) was found to enhance static transductions of TF-1 target cells. The relative effectiveness at increasing transduction efficiencies (TE) was: DOSPA > DC-Chol > DOTMA, resulting in average increases over nontreated controls of 11.9-, 6.2- and 1.2-fold, respectively. This pretreatment was found to be synergistic when combined with centrifugation, having the same order of effectiveness, and resulting in 57-, 35- and 27-fold increases over nontreated controls. For Lipofectamine and DC-Chol-DOPE liposomes, the combined approach yielded 2.2- and 1.3-fold increases over untreated centrifuged samples. Individual colonies picked from colony-forming unit granulocyte-macrophage assays of infected CD34+ cells were screened for the presence of the transgene by polymerase chain reaction (PCR). Colonies from cells infected using centrifugation were positive 27% of the time, while the combined approach had positive colonies 31 and 50% of the time for DC-Chol and Lipofectamine, respectively. The addition of protamine sulfate to the liposome-supernatant mixture during pretreatment was found to be inhibitory. With increasing centrifugal force, the TE of cells infected with Lipofectamine pretreated and untreated supernatants increased proportionally. However, the TE of the cells infected with the pretreated supernatants was significantly higher than the TE of the cells infected with untreated supernatants at all points examined. The increase in TE associated with liposomal pretreatment of retroviral supernatants was not shown to be attributed to a nonreceptor-mediated pathway for viral entry into the cell.
发现用阳离子脂质体DOTMA - DOPE(Lipofectin)、DC - Chol - DOPE和DOSPA - DOPE(Lipofectamine)对逆转录病毒上清液进行预处理可增强TF - 1靶细胞的静态转导。在提高转导效率(TE)方面的相对有效性为:DOSPA>DC - Chol>DOTMA,分别使平均转导效率比未处理的对照提高11.9倍、6.2倍和1.2倍。发现这种预处理与离心结合时具有协同作用,有效性顺序相同,使转导效率比未处理的对照分别提高57倍、35倍和27倍。对于Lipofectamine和DC - Chol - DOPE脂质体,联合方法比未处理的离心样品的转导效率分别提高2.2倍和1.3倍。通过聚合酶链反应(PCR)筛选从感染的CD34 +细胞的集落形成单位粒细胞 - 巨噬细胞试验中挑选出的单个集落中是否存在转基因。使用离心法感染的细胞集落有27%的时间呈阳性,而联合方法中DC - Chol和Lipofectamine的集落阳性时间分别为31%和50%。发现在预处理期间向脂质体 - 上清液混合物中添加硫酸鱼精蛋白具有抑制作用。随着离心力增加,用Lipofectamine预处理和未处理的上清液感染的细胞的转导效率成比例增加。然而,在所有检测点,用预处理上清液感染的细胞的转导效率显著高于用未处理上清液感染的细胞的转导效率。逆转录病毒上清液的脂质体预处理导致的转导效率增加并非归因于病毒进入细胞的非受体介导途径。